XORTX Therapeutics Inc.
XORTX Therapeutics Inc. (XRTX): ~10 mo cash runway. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
9.5 months
D/E 0.32 · 0% dilution
N/A
N/A
N/A
N/A
A transparent, data-derived signal for XORTX Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8M
Cash
$18.9M
Quarterly Burn
$6.1M
Runway
9.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Frequently asked questions
What is XORTX Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, XORTX Therapeutics Inc. has approximately 9.5 months of cash runway.
What is XORTX Therapeutics Inc.'s market capitalization?
XORTX Therapeutics Inc.'s market capitalization is approximately $3.8M.
Who is the CEO of XORTX Therapeutics Inc.?
Dr. Allen Warren Davidoff Ph.D. is the chief executive officer of XORTX Therapeutics Inc. (XRTX).
Get the full picture on XORTX Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.